Evidence map›Paper›PMID 29541405›Full record

ArticleOncotarget2018

Two novel colorectal cancer risk loci in the region on chromosome 9q22.32.

Jessada Thutkawkorapin, Hovsep Mahdessian, Tom Barber, Simone Picelli, Susanna von Holst, Johanna Lundin, Laura Valle, Vinaykumar Kontham, Tao Liu, Daniel Nilsson and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Jessada ThutkawkorapinDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Hovsep MahdessianDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Tom BarberThe Ludwig Center and Howard Hughes Medical Institute at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA.
Simone PicelliDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Susanna von HolstDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Johanna LundinDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Laura ValleHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Barcelona 08908, Spain.
Vinaykumar KonthamDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Tao LiuDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Daniel NilssonDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Xiang JiaoDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Annika LindblomDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm SE-17176, Sweden.
Karolinska Institutet · SEHoward Hughes Medical Institute · USInstitut Català d'Oncologia · ES

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Statistical Methods for Integrative Genomics in CancerP01CA196569 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul Marjoram · 2016 to 2026
$25.5M
Transdisciplinary Studies of Genetic Variation in Colorectal CancerU19CA148107 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GRUBER, STEPHEN B · 2010 to 2014
$11.1M
Using Functional Genomics to Inform Gene Environment Interactions for Colorectal CancerR01CA201407 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GAUDERMAN, WILLIAM JAMES, LE MARCHAND, LOIC · 2016 to 2020
$9.6M
MOLECULAR EPIDEMIOLOGY OF COLORECTAL CANCERR01CA081488 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRUBER, STEPHEN B · 1999 to 2008
$9.2M
The Epidemiology of Immune Responses in Colorectal CancerR01CA197350 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GRUBER, STEPHEN B · 2015 to 2019
$3.2M
NCI NIH HHS P01 CA196569NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA081488NCI NIH HHS R01 CA197350NCI NIH HHS R01 CA201407NCI NIH HHS U19 CA148107
6 · The paper itself

Abstract

Highly penetrant cancer syndromes account for less than 5% of all cases with familial colorectal cancer (CRC), and other genetic contribution explains the majority of the genetic contribution to CRC. A CRC susceptibility locus on chromosome 9q has been suggested. In this study, families where risk of CRC was linked to the region, were used to search for predisposing mutations in all genes in the region. No disease-causing mutation was found. Next, haplotype association studies were performed in the region, comparing Swedish CRC cases (2664) and controls (4782). Two overlapping haplotypes were suggested. One 10-SNP haplotype was indicated in familial CRC (OR 1.4,

Indexed as

association studycancer predispositionfamilial colorectal cancernext generation sequencingrisk haplotype

Identifiers

PMID29541405
PMCPMC5834248
OpenAlexW2789587607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.